GPhA responds to FTC’s attempt to quash ‘pay-for-delay’ deals
WASHINGTON The Federal Trade Commission again is going after settlements between branded and generic drug companies that it calls anticompetitive, the agency said.
In testimony Wednesday before the Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights, FTC chairman Jon Leibowitz spoke of the FTC’s goal of eliminating the patent settlements, which it derides as “pay-for-delay” deals. “Years of experience have proven that competitive markets work better than anything else to bring consumers lower prices, greater innovation and more choices among products and services,” Leibowitz said.
In a typical patent settlement scenario, a generic drug company will challenge a brand company’s patent on a drug by filing a regulatory approval application for a generic version with the Food and Drug Administration containing a Paragraph IV certification. Provided for under the Hatch-Waxman Act of 1984, the law that created an abbreviated approval pathway for generic drugs, a Paragraph IV certification is a legal assertion that the patent is invalid, unenforceable or won’t be infringed by a generic version of the drug.
The brand drug company typically will respond with a patent infringement suit, and often, rather than going to trial, the two companies will reach a settlement whereby the generic drug company agrees to hold off launching its version in exchange for the brand company paying money or agreeing not to launch an “authorized generic,” essentially the branded drug sold under its generic name at a discount. But in most cases, the settlements allow the generic company to launch its version months, or even years, ahead of the patent expiration.
The Generic Pharmaceutical Association, an industry lobbying group that has long criticized the FTC on the issue of patent settlements, lashed out at Leibowitz’s testimony. “Following the testimony today by commissioner Leibowitz before a Senate judiciary subcommittee, GPhA feels compelled to set the record straight,” GPhA president and CEO Kathleen Jaeger said. “The fact is that it is patents, not settlements, that protect the brands from generic competition. Despite claims to the contrary, settlements actually help bring affordable generic medicines to market sooner, to the benefit of consumers and the healthcare system.”
NACDS conference brings success, energy to the table
SAN DIEGO Uniting suppliers and manufacturers proved a success at National Association of Chain Drug Stores’ 2010 Marketplace Conference, which concluded Tuesday afternoon in San Diego.
Boasted as the largest convergence of drug, food, mass, club and value retailing in the United States, the NACDS Marketplace Conference featured new product showcases, category manager meet-and-greets and more. Representatives from such chains as Chain Drug Consortium, Costco, CVS Caremark, Kmart, Meijer, Shopko, Walgreens and Wegmans were present to provide visitors with industry insights.
Among the conference’s events were the Meet the Market program, Meet the Retailer/ How to Do Business With sessions and a product showcase on the exhibition floor. Evaluated by the retail attendees, winners of this year’s “Product Showcase” are:
- Baby Care Company: Bean-B-Clean Product: Bean-B-Clean (Scalp Massaging Brush)
- Consumables Company: Crunchies Food Co. Product: Crunchies (all natural freeze dried fruits and veggies)
- Cosmetics and Fragrances Company: U.S. Cotton, LLC Product: Swisspers exfoliating cotton facial cleansing pads
- General Merchandise Company: FGX International Product: LightSpecs by Foster Grant
- Healthcare/OTC Company: TECNIMED Product: Thermofocus, the original 5-1 non contact thermometer
- Home Healthcare Company: Drive Medical Design & Manufacturing Product: Glow & Go folding cane
- Personal Care/HBC Company: Zeno Corp. Product: Zeno Hot Spot blemish clearing device
“This year’s NACDS Marketplace Conference was an overall success and the atmosphere was full of energy,” said NACDS president and CEO Steve Anderson. “From the Meet the Market program to the education sessions and the exhibit floor, NACDS continues to provide attendees an effective and efficient meeting geared toward their needs.”
FDA releases sun safety video
SILVER SPRING, Md. Summer is a time when millions of Americans make their way to beaches, parks and vacation spots, but they also could be putting themselves at risk for skin and eye damage caused by ultraviolet radiation from the sun.
The Food and Drug Administration has posted a short video on its website designed to show consumers how to protect themselves from UV rays. The video features FDA dermatologist Jane Liedtka and FDA ophthalmologist Wiley Chambers explaining the need for sunscreen and sunglasses, and what kinds consumers should buy.